Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial

A Abideen Salako A Adesola Musa F Fehintola Ige A Adam Abdullahi A Ayorinde James S Sabdat Ekama O Oluwatosin Odubela I Ifeoma Idigbe O Olusola Ajibaye M Mazharul Altaf K Kazeem Adeneye F Folahanmi T. Akinsolu I Ifedola Olojo A Azuka Okwuraiwe H Henry Egharevba M Magaret Ekpenyong U Uchenna Elemuwa I Ifeoma Ezenyi F Fraden Bitrus O Olayemi Odubela A Abdulrasheed Oba G Ganiu Idris J Jimoh Yusuf I Ibukun Akande S Stephine Nwaiwu L Louisa Omale O Oluwatobiloba Oyewunmi A Adedoyin Agbabiaka O Olajumoke Eyinade J Joy Ogunwale A Abdullah Garba Y Yahya Bello B Baba Musa O Ogochukwu Ezejiofor B Ben Ejiro B Bamidele Iwalokun L Leah Rosenzweig O Obi Adigwe C Christianah Adeyeye F Faisal Shuaib W Witold Wicek Y Yohhei Hamada O Oliver Ezechi R Ravindra Gupta B Babatunde Salako

Abstract

Abstract Fractional dosing of vaccines is a viable strategy to extend COVID-19 vaccine supplies in resource-constrained settings. We did a triple-blinded, multi-site, randomized non-inferiority trial in Nigeria (PACTR202206754734018). Adults 18–65 years received full, half, or quarter primary doses of ChAdOx1 or Ad26.COV2.S, or full vs half doses of BNT162b2. Primary study outcome was seroconversion defined as ≥ 2.5-fold rise in anti-Spike IgG geometric-mean fold rise (GMFR) at day 28. A total of 1894 participants were enrolled between June 21, 2022, and January 25, 2023. 320 participants in the fractional dose group and 220 in the standard dose group completed follow-up and were included in the analysis. Seropositivity at baseline was high, at 68% (365/539). Seroconversion was comparable between standard and fractional doses (p = 0.822). For ChAdOx1, 31% achieved seroconversion at standard dose (16/52), 28% at half-dose (15/53), and 34% in quarter-dose (18/53). For Ad26.COV2.S, the proportions were 27% (28/105), 32% (22/68), and 30% (21/71) respectively. For BNT162b2, the proportions were 43% (27/63) and 39% (29/75) for standard- and half-dose. Serum neutralization showed ≥ twofold response across dosing. There were no serious adverse events. Fractional vaccine doses generated non-inferior immune responses compared to standard doses in the context of previous COVID-19. Protocol Registration: The protocol was registered with the Pan African Clinical Trials Registry (PACTR) PACTR202206754734018.

Article Details

Volume / Issue Vol. 15, Issue 1
Published July 29, 2025
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (45)

A

Abideen Salako

A

Adesola Musa

F

Fehintola Ige

A

Adam Abdullahi

A

Ayorinde James

S

Sabdat Ekama

O

Oluwatosin Odubela

I

Ifeoma Idigbe

O

Olusola Ajibaye

M

Mazharul Altaf

K

Kazeem Adeneye

F

Folahanmi T. Akinsolu

I

Ifedola Olojo

A

Azuka Okwuraiwe

H

Henry Egharevba

M

Magaret Ekpenyong

U

Uchenna Elemuwa

I

Ifeoma Ezenyi

F

Fraden Bitrus

O

Olayemi Odubela

A

Abdulrasheed Oba

G

Ganiu Idris

J

Jimoh Yusuf

I

Ibukun Akande

S

Stephine Nwaiwu

L

Louisa Omale

O

Oluwatobiloba Oyewunmi

A

Adedoyin Agbabiaka

O

Olajumoke Eyinade

J

Joy Ogunwale

A

Abdullah Garba

Y

Yahya Bello

B

Baba Musa

O

Ogochukwu Ezejiofor

B

Ben Ejiro

B

Bamidele Iwalokun

L

Leah Rosenzweig

O

Obi Adigwe

C

Christianah Adeyeye

F

Faisal Shuaib

W

Witold Wicek

Y

Yohhei Hamada

O

Oliver Ezechi

R

Ravindra Gupta

B

Babatunde Salako